ArticleBreast cancer (Dove Medical Press)2026
A Retrospective Analysis of a Serum Multi-Biomarker (CA153, TSGF, and CYFRA 21-1) Logistic Regression Model for Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurately predicting pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer remains challenging when relying on single biomarkers. We aimed to establish a composite serum model integrating CA153, tumor-supplied group of factors (TSGF), and CYFRA 21-1 to enhance predictive performance. Methods: This retrospective study included 258 breast cancer patients who received NAC at The First Hospital of Putian between January 2021 and December 2022. Eligible patients had histologically confirmed invasive breast cancer and complete clinical, pathological, and biomarker data. Patients with distant metastasis or incomplete serum data were excluded. Serum biomarkers (CA153, TSGF, and CYFRA 21-1) were measured before NAC. Univariate and multivariate logistic regression analyses were conducted to identify independent predictors of pCR, and receiver operating characteristic (ROC) curves were used to evaluate model performance. Results: Serum CA153, TSGF, and CYFRA 21-1 levels were significantly lower in patients achieving pCR than in non-pCR patients (CA153: 72.10 vs. 103.82 U/mL; TSGF: 129.77 vs. 188.12 U/mL; CYFRA 21-1: 10.16 vs. 17.05 ng/mL; all P < 0.001). Moderate positive correlations were observed among the three markers. Multivariate logistic regression confirmed CA153 (OR = 1.185), TSGF (OR = 1.062), and CYFRA 21-1 (OR = 1.395) as independent predictors of non-pCR. The composite serum model demonstrated excellent discrimination (AUC = 0.967, 95% CI: 0.949-0.985), with high sensitivity (0.980) and negative predictive value (0.968), outperforming each biomarker alone. Conclusion: The CA153-TSGF-CYFRA 21-1 serum composite model provides a simple, accurate, and non-invasive approach for predicting NAC response in breast cancer, with potential to support individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.